5. Severe Metabolic Acidosis

Quick Recap

Renal System, Protocol 5/7.

1. Systematic Approach to Acid-Base Analysis

Step 1 — Look at pH: low pH (acidemia) from low HCO3- OR high PCO2; high pH (alkalemia) from high HCO3- OR low PCO2.

Step 2 — Determine primary disorder: low pH + low HCO3- = metabolic acidosis; high pH + high HCO3- = metabolic alkalosis; low pH + high PCO2 = respiratory acidosis; high pH + low PCO2 = respiratory alkalosis.

Step 3 — If respiratory, determine acute vs chronic (see Respiratory Acid-Base disorders reference for full detail).

Step 4 — Apply compensation rules to distinguish simple vs mixed disorder (Section 2).

Step 5 — "Mind the gaps": anion gap, delta gap, urinary anion gap, osmolar gap (Section 3).

2. Compensation Rules (Expected Compensation — Deviation Signals a Mixed Disorder)

If measured PCO2/HCO3- deviates meaningfully from the expected compensation, a MIXED (not simple) acid-base disorder is present — this is the single most important discriminating step, and skipping it risks missing a second, potentially more dangerous concurrent process.

"Normal pH" does NOT mean normal acid-base status — watch for these mixed-disorder patterns hiding behind a seemingly reassuring pH:

• Normal pH + ↓PCO2 + ↓HCO3 = respiratory alkalosis + metabolic acidosis
• Normal pH + ↑PCO2 + ↑HCO3 = respiratory acidosis + metabolic alkalosis
• Normal pH + normal PCO2 + normal HCO3 + ↑AG = metabolic acidosis AND alkalosis occurring simultaneously (masking each other)

3. The Anion Gap Framework

AG = Na+ − (Cl- + HCO3-); normal 8-12 mEq/L (some sources cite 10±4).

CRITICAL: correct AG for hypoalbuminemia (extremely common in ICU patients) — for every 1 g/dL drop in albumin below 4 g/dL, ADD 2-2.5 to the calculated AG. A "normal" AG in a hypoalbuminemic ICU patient may actually represent a clinically significant elevated AG once corrected — failing to correct for albumin is one of the most common bedside errors in acid-base interpretation and can mask a real anion gap acidosis.

Adjusted AG = calculated AG + 2.5 x (4 − serum albumin in g/dL)

Causes of increased AG acidosis (mnemonic-organized):

Causes of normal (non-)AG acidosis — mnemonic HARDUP:

Hyperalimentation/hyperchloremia, Acetazolamide, Renal tubular acidosis, Diarrhea, Uremia (acute), Post-intubation hypocapnia. Also: pancreatic/biliary/intestinal fistulas, ostomy, cholestyramine/sevelamer, carbonic anhydrase inhibitors, ammonium chloride ingestion.

4. Delta Gap / Delta Ratio — Detecting Mixed Metabolic Disorders

Delta gap = delta AG − delta HCO3-, where delta AG = patient's AG − 12 (normal AG), and delta HCO3- = 24 (normal HCO3-) − patient's HCO3-.

Delta ratio = delta AG / delta HCO3-.

Normal delta gap (pure AG acidosis) = 0 ± 6; normal delta ratio ≈ 1.1.

• Delta gap/ratio significantly >1 (or delta gap >6 mEq/L): suggests a CONCOMITANT metabolic alkalosis and/or chronic respiratory acidosis (HCO3- retention) superimposed on the AG acidosis
• Delta gap/ratio significantly <1 (or delta gap <6 mEq/L, especially negative): suggests a CONCOMITANT normal-AG (hyperchloremic) metabolic acidosis and/or chronic respiratory alkalosis

This calculation is how a mixed metabolic acid-base disorder is uncovered when it is NOT obvious from the raw numbers alone — essential in complex ICU patients with multiple simultaneous processes (e.g., DKA with concurrent vomiting-induced alkalosis).

5. Urinary Anion Gap (UAG) — For Normal-AG Acidosis Workup

UAG = Urine Na+ + Urine K+ − Urine Cl-.

Normal: zero or slightly negative.

In normal-AG metabolic acidosis:

• NEGATIVE UAG (typically -20 to -50 mEq/L): kidney is appropriately increasing ammonium (NH4Cl) excretion in response to acidosis — indicates a NON-RENAL cause of bicarbonate loss (e.g., severe diarrhea) with intact renal acid-handling capacity
• POSITIVE UAG: kidney is FAILING to appropriately increase ammonium excretion — indicates a RENAL cause (renal tubular acidosis, CKD, acute renal failure)

This single calculation efficiently distinguishes GI-source from renal-source normal-AG acidosis, which have entirely different management pathways.

6. Osmolar Gap — Toxic Alcohol Screen

Osmolar gap = measured osmolality − calculated osmolality. Normal <10-20 mOsm/kg H2O.

An elevated osmolar gap in the setting of an elevated AG acidosis strongly suggests a TOXIC ALCOHOL ingestion (methanol, ethylene glycol) — both processes together (elevated AG + elevated osmolar gap) should trigger empiric consideration of fomepizole and urgent toxicology/nephrology involvement even before confirmatory levels return, given the narrow therapeutic window for these ingestions.

Important caveat: the osmolar gap NARROWS over time as the parent alcohol is metabolized to its toxic acid metabolites (which themselves drive the AG) — a normal osmolar gap late in the course does NOT exclude toxic alcohol ingestion if the AG remains elevated and the clinical history is suggestive.

7. Lactic Acidosis — Detailed Mechanism and Management

Mechanisms: increased pyruvate production (glycogenolysis/gluconeogenesis enzyme defects), decreased pyruvate utilization (pyruvate dehydrogenase/carboxylase defects), increased pyruvate-to-lactate conversion (increased metabolic rate: seizure, severe exercise, hypothermic shivering, shock/cardiac arrest/pulmonary edema, severe hypoxemia, CO poisoning, cyanide intoxication), and decreased lactate UTILIZATION (hypoperfusion, alcoholism, liver disease — the liver is the primary site of lactate clearance, so hepatic dysfunction itself can drive/sustain lactic acidosis independent of production).

Primary therapy: correct the underlying disorder and reverse circulatory failure — bicarbonate is NOT a substitute for treating the cause.

Bicarbonate use in lactic acidosis is CONTROVERSIAL:

• Consider if pH <7.1 OR loss of buffering capacity (bicarbonate <5 mEq/L)
• BICAR-ICU trial: limited data suggest a possible mortality benefit specifically at pH <7.20 in the context of concurrent AKI — this is the evidence basis for the expert-opinion threshold of pH 7.1-7.2 for bicarbonate consideration in life-threatening acidemia
• Bicarbonate risks: volume expansion, increased CO2 generation (can worsen intracellular acidosis paradoxically), hypernatremia, HYPOCALCEMIA (worsens cardiac contractility) — all of which can contribute to WORSENING cardiovascular status, the opposite of the intended effect

Alternative buffers (NOT demonstrated safe/effective in RCTs — use with caution, not first-line):

• THAM (tromethamine): buffers without generating CO2; RENALLY EXCRETED — can cause hyperkalemia, hypoglycemia, respiratory depression in anuric/oliguric patients; little outcome/mortality data exists despite long availability
• Carbicarb: equimolar sodium carbonate + sodium bicarbonate; theoretically reduces hypercapnia/intracellular acidosis risk vs bicarbonate alone
• Dichloroacetate: activates pyruvate dehydrogenase, increases pyruvate oxidation (reducing lactate formation) — mechanistically appealing, not established in outcome trials

Hemodialysis may be indicated in resistant cases, particularly with concurrent renal failure or when volume cannot accommodate IV bicarbonate administration. Most dialysate solutions have bicarbonate concentration 35-38 mEq/L.

Propylene glycol toxicity — an important, often-missed ICU-acquired cause: propylene glycol is the VEHICLE for continuous infusions of lorazepam, etomidate, phenytoin, nitroglycerin, and other agents; converts to pyruvate/lactate, causing lactate accumulation and an INCREASED OSMOLAR GAP. Discontinue the offending infusion if suspected — a reversible, iatrogenic cause worth actively screening for in any ICU patient on prolonged high-dose lorazepam infusion with unexplained lactic acidosis and osmolar gap.

8. Bicarbonate Deficit Calculation (When Bicarbonate Therapy Is Chosen)

Bicarbonate deficit (mEq) = apparent volume of distribution x target change in [HCO3-]

Apparent volume of distribution = total body weight (kg) x [0.4 + (2.4/HCO3-)]

(Note: the volume of distribution EXPANDS as the baseline bicarbonate falls lower — buffering capacity is less efficient at severe acidosis, requiring proportionally more bicarbonate per unit of desired correction.)

Worked example: 60kg patient, current HCO3- 5 mEq/L, target 12 mEq/L: Vd = 60 x [0.4 + 2.4/5] = 53L; target change = 7 mEq/L; total deficit = 53 x 7 = 371 mEq bicarbonate, administered over a MINIMUM of 4-8 hours with frequent HCO3-/pH monitoring — do not attempt rapid full correction.

Simplified alternative formula: Bicarbonate deficit (mEq) = 0.5 x body weight (kg) x (24 − [HCO3-]).

9. Chronic Metabolic Acidosis — A Different Management Paradigm

Chronic metabolic acidosis (typically CKD or renal tubular dysfunction) is managed very differently from acute acidosis — despite generally milder acidemia, the persistent acidic milieu drives bone demineralization, protein catabolism, and CKD progression if untreated. Oral alkali therapy (oral sodium bicarbonate) is usually sufficient and has been associated with GFR preservation, reduced proteinuria, and a modest mortality benefit in small studies — a proactive, outpatient-oriented therapy quite distinct from the acute-crisis bicarbonate calculus above.

10. Metabolic Alkalosis — Brief Cross-Reference

Most ICU cases from diuretics or gastric secretion loss (vomiting, NG suction). Other causes: bicarbonate administration, post-hypercapnic state, citrate (plasma exchange, massive transfusion, FFP). Classify as chloride-responsive (urine Cl- <20 mEq/L) vs chloride-resistant (urine Cl- >20 mEq/L) — directs whether saline-based repletion will correct the alkalosis or whether an alternative cause (e.g., mineralocorticoid excess) needs to be pursued. Renal insufficiency aggravates alkalosis by delaying bicarbonate excretion. Alkalemia promotes proton release from albumin, which can create a slight AG elevation even in pure metabolic alkalosis — a subtle confounder worth knowing when interpreting AG in a mixed picture.

11. Organ Support

Mechanical ventilation with attention to respiratory compensation capacity; hemodialysis for refractory/severe acidosis or when volume cannot accommodate bicarbonate; standard ICU supportive care targeting the underlying etiology (shock resuscitation for lactic acidosis, insulin/fluids for DKA, toxin-specific antidotes for toxic alcohols).

12. Consultation Matrix

13. Monitoring Framework

Serial ABG/VBG with recalculated AG (albumin-corrected), delta gap trending in complex/mixed cases, lactate trend, osmolar gap trend if toxic alcohol suspected, frequent HCO3-/pH monitoring during bicarbonate infusion, watch for hypocalcemia/volume overload with bicarbonate therapy.

14. Complications

Cardiovascular depression from severe acidemia (reduced cardiac contractility, reduced vasopressor responsiveness, arteriolar vasodilation), bicarbonate therapy complications (volume overload, hypernatremia, hypocalcemia, paradoxical intracellular/CSF acidosis from CO2 generation), THAM-related hyperkalemia/hypoglycemia in renal impairment, missed mixed disorders from incomplete gap analysis. Prevention: albumin-corrected AG calculation as routine practice, delta gap calculation in complex cases, cautious/monitored bicarbonate administration over hours not minutes. Rescue: hemodialysis for refractory severe acidosis.

15. Escalation & De-escalation

Escalate: pH <7.1-7.2 with hemodynamic compromise -> consider bicarbonate per BICAR-ICU-informed threshold, especially with concurrent AKI; refractory to medical therapy -> hemodialysis.

De-escalate: underlying cause reversed (shock resolved, DKA treated, toxin cleared), pH/HCO3- normalizing -> discontinue bicarbonate infusion, transition to monitoring, address chronic acidosis with oral alkali if CKD-related.

16. ICU Discharge Criteria

Acid-base status normalized or at a stable chronic baseline, underlying cause identified and treated, no ongoing hemodynamic compromise from acidemia, chronic acidosis (if present) on an appropriate oral alkali therapy plan.

17. Documentation & Medicolegal Checklist

18. Key Guidelines

Jaber S, Paugam C, Futier E, et al. Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU): a multicenter, open-label, randomised controlled, phase 3 trial. Lancet. 2018;392(10141):31-40.

19. Landmark Trials

BICAR-ICU trial — informs the pH 7.1-7.2 bicarbonate consideration threshold, with the strongest signal in patients with concurrent AKI specifically.

20. Controversies

Bicarbonate therapy in lactic acidosis remains genuinely controversial — BICAR-ICU provides only limited, subgroup-driven support (AKI patients specifically) rather than a broad mandate, and the risk profile (volume overload, hypocalcemia, paradoxical intracellular acidosis) means many intensivists remain conservative in its use. Alternative buffers (THAM, Carbicarb, dichloroacetate) all lack robust outcome data despite mechanistic appeal, leaving a genuine therapeutic gap for bicarbonate-intolerant patients. The precise clinical threshold for pursuing hemodialysis purely for acidosis correction (absent other RRT indications) is individualized rather than protocolized.

21. References

1. Wassermann MP. Metabolic Acid-Base Disorders. Washington Manual of Critical Care, 4th ed, 2025 (Ch. 27).
2. Pandit R, Pundpal GS. Arterial Blood Gases. ICU Protocols: A Step-wise Approach, 2nd ed. Springer; 2020 (Ch. 4, and Appendix B formula reference).
3. Jaber S, Paugam C, Futier E, et al. Sodium bicarbonate therapy for severe metabolic acidaemia in the ICU (BICAR-ICU). Lancet. 2018;392(10141):31-40.
4. Gauthier PM, Szerlip HM. Metabolic acidosis in the intensive care unit. Crit Care Clin. 2002;18(2):289-308.
5. Gehlbach BK, Schmidt GA. Bench-to-bedside review: treating acid-base abnormalities in the ICU — the role of buffers. Crit Care. 2004;8(4):259-265.
6. Kimmoun A, Novy E, Auchet T, et al. Hemodynamic consequences of severe lactic acidosis in shock states. Crit Care. 2015;19:175.
7. Arroliga AC, Shehab N, McCarthy K, et al. Relationship of continuous infusion lorazepam to serum propylene glycol concentration in critically ill adults. Crit Care Med. 2004;32(8):1709-1714.

See also: Acute Kidney Injury, Hyperkalemia, CRRT Indications (Renal System) for the dialytic and electrolyte management overlap in severe acidosis.